	US 11,712,448 B2
	Use of alginate oligomers as blood anticoagulants
Arne Dessen, Røyken (NO); and Philip Rye, Eiksmarka (NO)
Assigned to ALGIPHARMA AS, Sandvika (NO)
Appl. No. 15/106,196
Filed by ALGIPHARMA AS, Sandvika (NO)
PCT Filed Dec. 19, 2014, PCT No. PCT/GB2014/053808 § 371(c)(1), (2) Date Jun. 17, 2016, PCT Pub. No. WO2015/092437, PCT Pub. Date Jun. 25, 2015.
Claims priority of application No. 1322777 (GB), filed on Dec. 20, 2013.
Prior Publication US 2016/0331777 A1, Nov. 17, 2016
Int. Cl. A61K 31/734 (2006.01); A61P 7/02 (2006.01); A61K 31/702 (2006.01); A61M 1/36 (2006.01); A61L 33/08 (2006.01); A61K 31/715 (2006.01)

CPC A61K 31/734 (2013.01) [A61K 31/702 (2013.01); A61K 31/715 (2013.01); A61L 33/08 (2013.01); A61M 1/3673 (2014.02); A61P 7/02 (2018.01)]

35 Claims

1. An in vitro or ex vivo method for the prevention or inhibition of blood coagulation, said method comprising contacting a composition comprising blood plasma or a material with which said composition is, or may be, in contact, with an alginate oligomer, wherein said alginate oligomer contains 2 to 75 monomer residues of which at least 30% are guluronic acid residues, and wherein said monomer residues do not carry a sulfate group.